Nabla Bio, a Boston, MA-based next-generation antibody design company, announced the closing of an $11 million seed financing round. 

The round was co-led by Khosla Ventures and Zetta Venture Partners, with participation from Fifty Years, Cantos Ventures, and others.

The new funding will be used to accelerate the development of an AI-first protein design platform, enabling rapid end-to-end engineering of next-generation antibody therapeutics.

Company: Nabla Bio, Inc.

Raised: $11.0M

Round: Seed Round

Funding Month: December 2021

Lead Investors: Khosla Ventures and Zetta Venture Partners

Additional Investors: Fifty Years, and Cantos Ventures

Company Website: https://www.nabla.bio/

Software Category: AI-first protein design platform

About the Company: Nabla Bio is an antibody design company. The company’s AI-first protein design platform enables rapid engineering of best-in-class antibody therapeutics. The foundational technology was developed by CEO Surge Biswas, academic Co-Founder George Church and their team at Harvard, and has advanced the field of machine learning-guided protein modeling and design. The company has a fully functional wet lab to complement its machine learning capabilities. Nabla Bio is based in Boston, MA. 

Source: https://www.businesswire.com/news/home/20211206005050/en/Nabla-Bio-Closes-11M-Seed-Financing-led-by-Khosla-Ventures-and-Zetta-Venture-Partners